Fig. 3

Mean hsTnI by Cycle. a Mean hsTnI concentrations increased throughout treatment for all outcome groups, indicating cumulative cardiac injury. All values were below what would be clinically detected in a standard troponin screening. Measuring hsTnI during the period of chemotherapy treatment did not predict later heart function decline as measured by either b LVEF or c strain. d There was a statically significant increase between pre- and post- doxorubicin hsTnI values for patients during cycle 2 and cycle 4 (p-value = 0.0029, 0.0059 respectively), an effect not observed with cycle 1 or 3 (p-value = 0.7596, 0.2742 respectively)